Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29177963 | 0.84 | ESR1 (0.46) | ESR1ESR2PDE10AALDH1A1GLA | |
| SCHEMBL7253564 | 0.84 | ESR1 (0.55) | ESR1ESR2PDE10AALDH1A1GLA | |
| SCHEMBL7126854 | 0.84 | ALDH1A1 (0.46) | ESR1ESR2PDE10AALDH1A1GLA | |
| SCHEMBL28861333 | 0.83 | ESR1 (0.57) | ESR1ESR2PDE10AALDH1A1GLA | |
| SCHEMBL30527881 | 0.81 | ALDH1A1 (0.52) | ESR1ESR2PDE10AALDH1A1GLA | |
| SCHEMBL9755342 | 0.81 | ALDH1A1 (0.52) | ESR1ESR2PDE10AALDH1A1GLA | |
| Biphenyl SCHEMBL28506015 | 0.77 | PDE10A (0.54) | ESR1ESR2PDE10AALDH1A1GLA | |
| SCHEMBL28441223 | 0.77 | ESR1 (0.62) | ESR1ESR2PDE10AALDH1A1GLA | |
| SCHEMBL28375096 | 0.76 | ALOX5 (0.44) | ESR1ESR2PDE10AALDH1A1HPGD | |
| SCHEMBL14677000 | 0.75 | CYP1A2 (0.45) | ESR1ESR2PDE10AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122060343-A | Marker comprising dibromopyridazindione for immunoassays and methods of making and using the same | 美国西门子医学诊断股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260008819-A1 | CYCLOSPORINE-ACRIDINIUM ESTERS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2026-01-08 | — | — | US | claimed |
| EP-4638467-A1 | CYCLOSPORINE-ACRIDINIUM ESTERS AND METHODS OF PRODUCTION AND USE THEREOF | Siemens Healthcare Diagnostics Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2025096611-A1 | REAGENT COMPOSITIONS FOR IMMUNOASSAYS AND USE OF THE SAME IN DETECTION OF CANCER ANTIGEN 19-9 | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2024137034-A1 | CYCLOSPORINE-ACRIDINIUM ESTERS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-20240010841-A1 | LABELS COMPRISING DIBROMOPYRIDAZINEDIONES FOR IMMUNOASSAYS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-01-11 | — | — | US | claimed |
| WO-2022126055-A1 | LABELS COMPRISING DIBROMOPYRIDAZINEDIONES FOR IMMUNOASSAYS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2022-06-16 | — | — | WO | claimed |
| CN-122060343-A | Marker comprising dibromopyridazindione for immunoassays and methods of making and using the same | 美国西门子医学诊断股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260008819-A1 | CYCLOSPORINE-ACRIDINIUM ESTERS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4638467-A1 | CYCLOSPORINE-ACRIDINIUM ESTERS AND METHODS OF PRODUCTION AND USE THEREOF | Siemens Healthcare Diagnostics Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025096611-A1 | REAGENT COMPOSITIONS FOR IMMUNOASSAYS AND USE OF THE SAME IN DETECTION OF CANCER ANTIGEN 19-9 | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024137034-A1 | CYCLOSPORINE-ACRIDINIUM ESTERS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240010841-A1 | LABELS COMPRISING DIBROMOPYRIDAZINEDIONES FOR IMMUNOASSAYS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-01-11 | — | — | US | disclosed |
| WO-2022126055-A1 | LABELS COMPRISING DIBROMOPYRIDAZINEDIONES FOR IMMUNOASSAYS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008819-A1 | CYCLOSPORINE-ACRIDINIUM ESTERS AND METHODS OF PRODUCTION AND USE THEREOF | CYCS, CHP1, IL2RA | ESR1 2510/4885ESR2 1121/4885PDE10A 4450/4885 |
| US-20240010841-A1 | LABELS COMPRISING DIBROMOPYRIDAZINEDIONES FOR IMMUNOASSAYS AND METHODS OF PRODUCTION AND USE THEREOF | DDT, HLCS, BTD | ESR1 1625/4885ESR2 3576/4885PDE10A 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.